Scholarlink

Background <p>Immunotherapy, remarkably immune checkpoint inhibitors, has shown significant efficacy and survival benefits in patients with various solid tumors. Although T lymphocytes have been extensively studied as the primary target cells, the role and application of B cells in solid tumor immunotherapy remain less understood. </p> Methods <p>In this study, we conducted a bibliometric analysis of articles on solid tumor immunotherapy related to B cells, published from 2003 to March 28, 2024, in the Web of Science Core Collection. Co-authorship and keyword co-occurrence analyses were performed using VOSviewer, while CiteSpace was used to identify burst keywords and references.</p> Results <p>A total of 1995 publications were analyzed, revealing a year-on-year increase in articles. The most common keywords are “immunotherapy” and “expression”. The most frequently referenced publications focused on tertiary lymphoid structures and B-cell markers. The United States and China are the largest contributors to this field, with Frontiers in Immunology being the most prolific journal. This study provides a comprehensive overview of over 20 years of B cell and immunotherapy research in solid tumors, identifying key countries, institutions, authors, journals, and publications.</p> Conclusions <p>The findings offer valuable insights into the relationship between B cells and immunotherapy in solid tumors. This study primarily unveils the current research hotspots concerning the role of B cells in immunotherapy, encompassing both fundamental research and clinical trials, as well as the accelerating emergence of an increasing number of B-cell-centric immunotherapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月22日

查看全文
  • Shuman Kuang,
  • Mingjian Piao,
  • Chengjie Li,
  • Nan Zhang,
  • Jiongyuan Li,
  • Shuofeng Li,
  • Binhe Tian,
  • Lijin Zhao,
  • Haitao Zhao

摘要

Background

Immunotherapy, remarkably immune checkpoint inhibitors, has shown significant efficacy and survival benefits in patients with various solid tumors. Although T lymphocytes have been extensively studied as the primary target cells, the role and application of B cells in solid tumor immunotherapy remain less understood.

Methods

In this study, we conducted a bibliometric analysis of articles on solid tumor immunotherapy related to B cells, published from 2003 to March 28, 2024, in the Web of Science Core Collection. Co-authorship and keyword co-occurrence analyses were performed using VOSviewer, while CiteSpace was used to identify burst keywords and references.

Results

A total of 1995 publications were analyzed, revealing a year-on-year increase in articles. The most common keywords are “immunotherapy” and “expression”. The most frequently referenced publications focused on tertiary lymphoid structures and B-cell markers. The United States and China are the largest contributors to this field, with Frontiers in Immunology being the most prolific journal. This study provides a comprehensive overview of over 20 years of B cell and immunotherapy research in solid tumors, identifying key countries, institutions, authors, journals, and publications.

Conclusions

The findings offer valuable insights into the relationship between B cells and immunotherapy in solid tumors. This study primarily unveils the current research hotspots concerning the role of B cells in immunotherapy, encompassing both fundamental research and clinical trials, as well as the accelerating emergence of an increasing number of B-cell-centric immunotherapies.